Business Context and Reporting Period
This Form 8-K is a current report filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on March 29, 2021, with the earliest event reported on that date. The filing addresses executive compensation arrangements and equity award accelerations related to a potential Sale Event.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on contractual amendments and equity plan administration.
Material Changes and Executive Actions
- Amendment to Transition Services Agreement: On April 1, 2021, the Company amended its agreement with former Chief Scientific Officer and Chief Medical Officer Kevin G. Peters, M.D. The amendment extended the period for severance eligibility prior to a change of control from three months to five months.
- Consulting Services Agreement: Dr. Peters entered into a new consulting agreement effective April 1, 2021, at a rate of $300 per hour. The term is set to end on July 1, 2021, unless terminated earlier. His existing stock options will continue to vest during this period.
- Acceleration of Equity Awards: On March 29, 2021, the Board of Directors accelerated equity awards for certain individuals, including President and Founder Joseph H. Gardner, Ph.D., and Vice President of Finance Regina Marek. These awards became fully vested and exercisable upon the effective time of a Sale Event.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, operational outlook, or general risk factors. The primary contingency noted is the definition of a "Sale Event," which triggers the acceleration of equity awards for named executive officers. The filing references attached exhibits for the complete text of the amended agreements.
Key Facts for Investor Verification
- Verify the specific definition of "Sale Event" in the Company's 2017 Stock Option and Incentive Plan to understand the trigger for equity acceleration.
- Review the attached Exhibit 10.1 and 10.2 for the full terms of the amended transition and consulting agreements with Dr. Peters.
- Confirm the total number of shares or option value accelerated for Dr. Gardner and Ms. Marek, as specific quantities are not listed in the summary text.
- Note the discrepancy between the requested company name (Whitehawk Therapeutics) and the filing registrant (Aerpio Pharmaceuticals).